Strengths and forms
The table is set at the top of the page
Searches of ClinicalTrials.gov and PubMed returned no label and no human trial of rosuvastatin on a steroid cycle or with a cycle length. The label puts the 20 mg tablet in bottles of 90 and the 40 mg tablet in bottles of 30.1 The 5 mg and 10 mg tablets are also supplied in bottles of 90.1 It describes tablets for oral use and names no capsule or oral powder form.1 Searches of DailyMed for a rosuvastatin sprinkle capsule returned no labels, and nothing on mixing, water or a U-100 syringe turned up.
Label dose range and adjustments
The label gives the adult range as 5 to 40 mg once daily, depending on indication, LDL-C and individual cardiovascular risk.1 It describes the route as oral, as a single dose at any time of day, with or without food, tablets swallowed whole.1 It says to assess LDL-C as early as 4 weeks after starting and adjust the dose if necessary.1
For Asian patients the label gives a start of 5 mg once daily.1 In severe renal impairment (CLcr less than 30 mL/min/1.73 m2) not on hemodialysis, the label gives a starting dose of 5 mg and a maximum of 10 mg once daily.1 With cyclosporine the dose is not to exceed 5 mg once daily, and with gemfibrozil use is to be avoided or, if unavoidable, started at 5 mg and held to 10 mg once daily.1
What the named trials used
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| JUPITER (Ridker, 2008) | Rosuvastatin 20 mg daily or placebo2 | 17,802 apparently healthy men and women with LDL cholesterol under 130 mg per deciliter and high-sensitivity C-reactive protein of 2.0 mg per liter or higher2 | Stopped after a median follow-up of 1.9 years (maximum 5.0)2 |
| STELLAR (Jones, 2003) | Rosuvastatin 10, 20, 40 or 80 mg; atorvastatin 10, 20, 40 or 80 mg; simvastatin 10, 20, 40 or 80 mg; or pravastatin 10, 20 or 40 mg, open-label3 | 2,431 adults with hypercholesterolemia (LDL cholesterol 160 to under 250 mg/dl, triglycerides under 400 mg/dl)3 | 6 weeks3 |
| Label triglyceride study | A single daily dose (5 to 40 mg), or placebo, double-blind1 | Adults with baseline TG levels from 273 to 817 mg/dL: placebo n=26, 5 mg n=25, 10 mg n=23, 20 mg n=27, 40 mg n=251 | 6 weeks1 |
The 80 mg arm in STELLAR is above the label maximum of 40 mg once daily.31 In the label's pediatric HoFH study, a randomized, double-blind, placebo-controlled cross-over study in 14 patients aged 7 to 15, each patient took 20 mg and placebo in two treatment periods in random order, and 13 completed both periods.1
Cycles and steroid use
Searches of DailyMed, ClinicalTrials.gov and PubMed returned no label, no human trial and no stability data for rosuvastatin on a steroid cycle or with a cycle length. For cycles in general, see the cycles guide, and for the class, post-cycle and ancillaries.
Storage
The label gives storage at controlled room temperature, 20ºC to 25ºC, with excursions permitted between 15°C and 30°C, protected from moisture.1 That is the dry tablet, and the searches returned no data for any after-mixing storage.
Frequently asked questions
Does the dose change the label's myopathy risk?
The label says myopathy risk is greater at 40 mg daily than at lower doses.1
What adverse reactions does the label list most often?
The label lists headache, nausea, myalgia, asthenia and constipation, each at 2% or more.1
Does the label give doses for children?
The label gives 5 mg to 10 mg once daily at ages 8 to under 10 with HeFH, 5 mg to 20 mg once daily from age 10 with HeFH, and 20 mg once daily from age 7 with HoFH.1
References
- AstraZeneca (DailyMed). These highlights do not include all the information needed to use CRESTOR safely and effectively. See full prescribing information for CRESTOR. CRESTOR ® (rosuvastatin) tablets, for oral use Initial U.S. Approval: 2003. 2026. dailymed.nlm.nih.gov
- PubMed. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. 2008. pubmed.ncbi.nlm.nih.gov
- PubMed. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). 2003. pubmed.ncbi.nlm.nih.gov